Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Common diabetes drug may shield kidneys from chemo damage

NCT ID NCT07018622

Disease control Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether dapagliflozin, a drug used for diabetes, can prevent kidney damage caused by platinum-based chemotherapy in people with solid tumors. About 46 participants will receive either dapagliflozin or a placebo for a few days around their chemo session. Researchers will measure kidney injury markers in urine to see if the drug offers protection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dapagliflozin (a diabetes drug that helps protect kidneys)
What this could lead to
If it works, this could offer a simple way to protect kidneys during chemotherapy, reducing treatment delays and improving cancer outcomes.
What could go wrong
This is a small, early-phase trial (46 people) testing a biomarker, not a proven benefit. The drug may not reduce kidney injury or could cause side effects like dehydration or electrolyte imbalances.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 46 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent form * Diagnosis of a solid tumor requiring a platinum-based chemotherapy regimen (cisplatin or carboplatin) * Expected survival \> 4 months * ECOG performance status 0-2 Exclusion Criteria: * History of nephrectomy * History of kidney transplant * Concurrent use of known nephrotoxic drugs (e.g., aminoglycosides, amphotericin B, cyclophosphamide, ifosfamide, methotrexate) * Type 1 diabetes mellitus * Poorly controlled type 2 diabetes (HbA1c \> 8% or fasting glucose \> 200 mg/dL in the past month) * Active glomerulopathy * Prior use of SGLT2 inhibitors or current indication for their use * eGFR \< 20 ml/min/1.73 m² * Active urinary tract infection * Unresolved obstructive uropathy * Participation in another clinical trial * History of recurrent genitourinary infections

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cisplatin nephrotoxicity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cisplatin toxicity neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cisplatin nephrotoxicity Solid tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán"

    RECRUITING

    México, Tlalpan, 14080, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.